Abstract: The present invention relates to a light luminescent particle comprising a nanosized light emitting material, and use of said light luminescent particle. The present invention further relates to a composition comprising a light luminescent particle, an optical medium, and an optical device. The present invention also relates to method for preparing of said luminescent particle.
Abstract: The invention is directed towards stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid and its hemisulfate salt as well as pharmaceutical compositions and uses thereof in therapy, preferably chemotherapy.
Type:
Application
Filed:
May 17, 2019
Publication date:
September 5, 2019
Applicant:
MERCK & CIE
Inventors:
Rudolf MOSER, Viola GROEHN, Thomas EGGER, Thomas AMMANN
Abstract: The invention relates to a liquid-crystalline medium which comprises at least one compound of the formula I, in which R1, R1*, Z1, Z2 and L1-3 have the meanings defined herein, and to the use thereof for an active-matrix display, in particular based on the VA, PSA, PS-VA, PALC, FFS, PS-FFS, PS-IPS or IPS effect.
Type:
Grant
Filed:
October 28, 2016
Date of Patent:
September 3, 2019
Assignee:
MERCK PATENT GMBH
Inventors:
Harald Hirschmann, Monika Bauer, Martina Windhorst, Marcus Reuter, Constanze Brocke, Rocco Fortte, Matthias Bremer, Sabine Schoen
Abstract: The present invention relates inter alia to novel organic metal complexes comprising, e.g., platinum and specific side groups, their preparation und their use in electronic devices.
Abstract: The present invention is directed to tricyclic compounds of formula (I), (Ia) or (Ib) which are inhibitors of one or more mutant IDH enzymes. The present invention is also directed to uses of these tricyclic compounds in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.
Type:
Grant
Filed:
October 25, 2016
Date of Patent:
September 3, 2019
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
David J. Witter, Tesfaye Biftu, Purakkattle Biju, Stephane L. Bogen, Qingmei Hong, Chunhui Huang, Xianhai Huang, Bing Li, Min K. Park, David L. Sloman
Abstract: A separation unit is a configuration that is arranged vertically, and thus bubbles generating from the electrode will not negatively influence the contact location between the transfer membrane and separation unit. An anode (32) is arranged at a position separated by a certain distance in the conveying direction (X) of the transfer membrane (1) from the dispensing part (50a) of an electrophoresis gel chip (50). An insulating electrode cover (35) for setting free bubbles generating from the anode (32) is arranged at an upper part of the anode (32).
Abstract: The invention relates to a method for determining ammonium or ammonia in aqueous samples in accordance with the known Berthelot method, wherein the risk of incorrectly low results is greatly reduced by additionally measuring the extinction in the absorption range of the nitroprusside used as a catalyst.
Abstract: Compounds of Formula (I): (Formula (I)) and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.
Abstract: The present invention relates to a liquid crystal (LC) medium comprising polymerisable compounds, to a process for its preparation, to its use for optical, electro-optical and electronic purposes, in particular in LC displays, and to LC displays comprising it.
Type:
Application
Filed:
October 16, 2017
Publication date:
August 29, 2019
Applicant:
MERCK PATENT GMBH
Inventors:
Nils GREINERT, Matthias BREMER, Patrick SUESS, Christian SCHOENEFELD, Jochen SIEBERLING, Renate SEEGER, Anna Lisa HAWLITSCHEK
Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and eribulin or a pharmaceutically acceptable salt thereof, and the use of the combination therapies for the treatment of urothelial cancer.
Abstract: The invention relates to bimesogenic compounds of formula I wherein R11, R12, MG11, MG12, X11, X12 and Sp1 have the meaning given in claim 1, to the use of bimesogenic compounds of formula I in liquid crystal media and particular to flexoelectric liquid crystal devices comprising a liquid crystal medium according to the present invention.
Type:
Grant
Filed:
December 8, 2015
Date of Patent:
August 27, 2019
Assignee:
Merck Patent GmbH
Inventors:
Detlef Pauluth, Kevin Adlem, Owain Llyr Parri, Rachel Tuffin, Hassan Arasi, Patricia Eileen Saxton
Abstract: The present invention relates to novel compounds containing fluorinated end groups, to the use thereof as surface-active substances, and to compositions comprising these compounds.
Abstract: The present application relates to a material comprising a monoarylamine of a defined formula and a p-dopant of a defined formula. The present application further relates to the use of said material in an organic layer of an electronic device, the device preferably being an organic electroluminescent device (OLED).
Type:
Grant
Filed:
September 25, 2015
Date of Patent:
August 27, 2019
Assignee:
Merck Patent GmbH
Inventors:
Frank Voges, Frank Stieber, Philipp Stoessel, Teresa Mujica-Fernaud, Christof Pflumm, Joachim Kaiser
Abstract: The present invention relates to a process for the vacuum purification of chemical compounds and to an apparatus for carrying out this process.
Abstract: The present invention relates to liquid-crystalline media (LC media) having negative or positive dielectric anisotropy comprising self-aligning mesogens (SAMs) which effect homeotropic (vertical) alignment of the LC media at a surface or the cell walls of a liquid-crystal display (LC display). The invention therefore also encompasses LC displays having homeotropic alignment of the liquid-crystalline medium (LC medium) without conventional imide alignment layers. The LC media may be supplemented by a polymerisable or polymerised component, which serves for stabilisation of the alignment, for adjustment of the tilt angle and/or as passivation layer.
Type:
Application
Filed:
April 29, 2019
Publication date:
August 22, 2019
Applicant:
MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG